Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for ...
ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company ...
Welcome to Fierce Pharma's regulatory tracker for the first half of 2026. | In this tracker, Fierce Pharma is recording the ...
A complete response letter is a formal communication from the FDA indicating that an application cannot be approved in its present form. In the case of Outlook Therapeutics, the FDA noted that while ...
The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...
Benzinga on MSN
Top 5 stocks to watch today | January 2nd
US stock futures are trading higher this Friday morning as investors react to developments across Big Tech, semiconductors, ...
Corcept sought FDA approval despite finding relacorilant was statistically no better than placebo in one of two Phase III ...
TipRanks on MSN
FDA issues new setback for Outlook Therapeutics’ LYTENAVA
Outlook Therapeutics ( ($OTLK) ) has shared an update. On December 31, 2025, Outlook Therapeutics reported that the U.S. Food and Drug ...
Outlook Therapeutics' stock fell to a new low due to FDA rejection of its Lytenava filing for wet AMD. Efficacy evidence ...
ASML (NASDAQ: ASML) are up 4.9% after Aletheia Capital double-upgraded the European-listed shares of the chip equipment maker ...
Outlook Therapeutics has received the US FDA's CRL regarding the BLA resubmission for ONS-5010/LYTENAVA to treat wet AMD.
Detailed price information for Outlook Therapeutics Inc (OTLK-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback